These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 7831441)

  • 1. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates.
    Casey DE
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S55-9. PubMed ID: 7831441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates.
    Casey DE
    Psychopharmacol Bull; 1989; 25(3):457-9. PubMed ID: 2516634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics.
    Casey DE
    Psychopharmacol Bull; 1991; 27(1):47-50. PubMed ID: 1677773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L; Hansen L; Mørkeberg F; Gerlach J
    Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.
    Casey DE
    Psychopharmacology (Berl); 1992; 107(1):18-22. PubMed ID: 1534177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic and serotonergic aspects of acute extrapyramidal syndromes.
    Casey DE
    Psychopharmacol Ser; 1993; 10():101-10. PubMed ID: 8103220
    [No Abstract]   [Full Text] [Related]  

  • 7. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys.
    Casey DE
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):134-40. PubMed ID: 8935808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.
    Heintz R; Casey DE
    Psychopharmacology (Berl); 1987; 93(2):207-13. PubMed ID: 2827216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms.
    Prus AJ; Baker LE; Meltzer HY
    Pharmacol Biochem Behav; 2004 Feb; 77(2):199-208. PubMed ID: 14751446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
    Peacock L; Gerlach J
    Psychopharmacology (Berl); 1999 Jun; 144(3):189-97. PubMed ID: 10435384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes.
    Dose M
    Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():3-13. PubMed ID: 11072761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
    Gil-ad I; Shtaif B; Shiloh R; Weizman A
    Cell Mol Neurobiol; 2001 Dec; 21(6):705-16. PubMed ID: 12043843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.